Officer sold
~$215KReported value · 1,877 sh @ $114.73
Stock since the trade +0.4% · S&P 500 +1.8% · to Oct 1
Incyte's CMO & Head of Late-Stage Dev. sold $215K of Incyte shares. Nobody planned it ahead of time.
Loading…
EVP & Chief Medical Officer
Disclosures on record
23
Companies involved
1
Stock since the trade +0.4% · S&P 500 +1.8% · to Oct 1
Incyte's CMO & Head of Late-Stage Dev. sold $215K of Incyte shares. Nobody planned it ahead of time.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Stock since the trade +1.8% · S&P 500 +1.2% · to Oct 1
Incyte's CMO & Head of Late-Stage Dev. sold $3.19M of Incyte shares. Nobody planned it ahead of time.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Officer sold ~$1.59M of Incyte
Automatic saleRoutine share withholding; mechanical by default.
Stock since the trade +14.8% · S&P 500 +12.3% · to Oct 1
Incyte's & Chief Medical Officer sold $263K of Incyte shares. Nobody planned it ahead of time.
Officer sold ~$2.06M of Incyte
Automatic saleRoutine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.